HealthTrending
CVS Health agreed to pay $315 million to resolve Justice Department allegations that it illegally filled controlled substance prescriptions and billed federal programs. The settlement includes new DEA safeguards.
By Hermes-Vector AI Desk
CVS Health has agreed to pay $315 million to resolve allegations by the U.S. Department of Justice (DOJ) that the pharmacy chain illegally filled prescriptions for opioids and other controlled substances. The government alleged that CVS knowingly dispensed medications that lacked a legitimate medical purpose and subsequently sought reimbursement from Medicare and other federal health care programs.
The settlement resolves a civil lawsuit filed by the United States on Dec. 13, 2024, in the U.S. District Court for the District of Rhode Island. The allegations cover prescriptions filled between October 2013 and December 2025. According to the DOJ, CVS filled prescriptions involving excessive quantities of opioids, early refills, and dangerous drug combinations known as "trinity" prescriptions, which include an opioid, a benzodiazepine, and a muscle relaxant.
Prosecutors alleged that CVS pharmacists ignored "red flags" indicating that prescriptions were illegitimate. The DOJ also claimed that the company filled prescriptions from "pill mill" prescribers who issued large numbers of controlled substance prescriptions without a medical purpose. The government further alleged that CVS’s corporate performance metrics, incentive compensation, and staffing policies prioritized profits over patient safety.
CVS disputed the government's allegations and did not admit wrongdoing as part of the settlement. In addition to the monetary payment, CVS entered into a memorandum of agreement with the Drug Enforcement Administration (DEA). This agreement requires CVS to establish a hotline for employees and the public to report suspected illegal dispensing, proactively monitor dispensing patterns at its pharmacies, and implement procedures to evaluate prescribers suspected of illegal prescribing.
Associate Attorney General Stanley E. Woodward Jr. stated, "Not only does this settlement hold bad actors accountable for their fraudulent activities, but Americans are safer because of it." Assistant Attorney General Brett A. Shumate noted that the remedial measures, including proactive monitoring, "will provide critical protections for patients and federal healthcare programs."
The lawsuit originated from a whistleblower case filed by Hillary Estright, a former CVS employee, under the False Claims Act. The amount to be recovered by the private whistleblower has not yet been determined.
The period of alleged violations overlaps with the tenure of Helena Foulkes, who served as president of CVS from 2014 to 2018 and is currently a Democratic gubernatorial candidate in Rhode Island. GoLocalProv reported that many violations occurred while Foulkes oversaw CVS pharmacies or served as president. Foulkes has not responded to questions regarding the violations. Zachary A. Cunha, the U.S. Attorney for the District of Rhode Island when the lawsuit was announced, stated in 2024, "This lawsuit alleges that CVS failed to exercise its critical role as gatekeeper of dangerous prescription opioids and, instead, facilitated the illegal distribution of these highly addictive drugs."
This settlement marks a significant financial resolution in the federal government's ongoing efforts to combat the opioid epidemic by targeting pharmacy practices. It follows a previous $5 billion settlement by CVS in 2022 involving state, local, and tribal governments. The inclusion of specific operational safeguards mandated by the DEA highlights a shift toward stricter regulatory oversight of controlled substance dispensing practices.
Sources
This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.
The day's checked news, by email
One short email a day with the top stories. Free, and you can unsubscribe in one click.
Or follow for the latest news:
HealthTrending
A prospective study found that a commercially available enzyme supplement targeting FODMAPs significantly reduced irritable bowel syndrome symptoms over four weeks, though researchers caution that randomized trials are needed.
The College of Physicians and Surgeons of Ontario approved changes requiring opioid agonist therapy for safer supply prescriptions and mandating supervised dosing to reduce diversion.
